Genistein potentiates Centchroman induced antineoplasticity in breast cancer via PI3K/Akt deactivation and ROS dependent induction of apoptosis

In this study, we report that the dietary isoflavone genistein (GN) synergistically improved antineoplasticity of CC in breast cancer by arresting cells at G2/M phase culminating in ROS dependent apoptosis. The combination of CC plus GN caused dysregulation of Bax and Bcl-2 ratio inducing mitochondrial dysfunction, activation of Caspase-3/7, -9 and PARP cleavage. Further, combination significantly suppresses phosphorylation of PI3K/Akt/NF-κB, enhancing apoptosis. Additionally, combination markedly reduced tumor growth compared to CC and GN alone in mouse 4T1 breast tumor model.SignificanceTogether, these studies suggest that GN represents a potential adjunct molecule whose role in CC induced apoptosis deserves attention.Graphical abstract
Source: Life Sciences - Category: Biology Source Type: research

Related Links:

ConclusionDirect-to-implant IBR after skin-sparing mastectomy is a viable option for breast cancer patients undergoing neoadjuvant chemotherapy.ResumenIntroducciónLa reconstrucción inmediata (RMI) tras mastectomía en pacientes que han recibido quimioterapia neoadyuvante (QTNA) sigue siendo controvertida. El objetivo de este estudio es analizar y comparar resultados oncológicos y las tasas de complicaciones y reintervención en pacientes sometidas a QTNA y un grupo control.MétodosAnálisis observacional retrospectivo de casos-controles. Pacientes con cáncer de mama inter...
Source: Cirugia Espanola - Category: Surgery Source Type: research
Condition:   Breast Cancer Interventions:   Drug: GDC-0077;   Drug: Placebo;   Drug: Palbociclib;   Drug: Fulvestrant Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: SAR439859;   Drug: letrozole Sponsor:   Sanofi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Triple Negative Breast Neoplasms Interventions:   Biological: Pembrolizumab;   Drug: Olaparib;   Drug: Carboplatin;   Drug: Gemcitabine Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Intervention:   Other: FR-Mask Sponsor:   China Medical University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Neoplasm Female;   Symptom Cluster;   Tai ji Interventions:   Other: wait list control;   Behavioral: tai chi group Sponsors:   Charles Darwin University;   The Affiliated Hospital Of Southwest Medical University;   The Affiliated Hospital of Putian University;   Shenzhen Sixth People's Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8 Interventions:   Biological: Pembrolizumab;   Drug: Tamoxifen;   Drug: Vorinostat Sponsors:   University of California, San Francisco;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Triple negative breast cancer is the hardest form to treat and most fatal version of the disease. Mt Sinai researchers discovered a protein that May fuel the cancer and a drug to stop it in animals.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Immunotherapy, Ahead of Print.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
This study was undertaken to investigate the antibone-metastatic activities and mechanisms of WSZG extract by evaluating the effect of this formula on the cross-talk between bone marrow-derived mesenchymal stem cells (BMSCs) and breast cancer cells in triggering epithelial-mesenchymal transition (EMT) in vivo and in vitro. The results demonstrated that BMSCs might enhance the invasive and metastatic potentials of breast cancer cells as a consequence of EMT induction through direct cell-to-cell contact. WSZG treatment remarkably suppressed motility, invasion, EMT-related gene, and protein markers in BMSC-conditioned breast ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Diets | Nutrition | Soy isoflavones | Study | Toxicology